AtriCure (NASDAQ:ATRC) Given New $58.00 Price Target at UBS Group
AtriCure (NASDAQ:ATRC – Free Report) had its target price lowered by UBS Group from $60.00 to $58.00 in a report released on Wednesday morning,Benzinga reports. UBS Group currently has a buy rating on the medical device company’s stock. ATRC has been the topic of several other research reports. Piper Sandler lifted their price objective on […]
AtriCure (NASDAQ:ATRC – Free Report) had its target price lowered by UBS Group from $60.00 to $58.00 in a report released on Wednesday morning,Benzinga reports. UBS Group currently has a buy rating on the medical device company’s stock. ATRC has been the topic of several other research reports. Piper Sandler lifted their price objective on […]
